ライフサイエンスコーパス: HDL cholesterol

1 olic blood pressure [SBP/DBP], total [TC] or HDL-cholesterol).

2 t consumption was positively associated with HDL cholesterol.

3 DL cholesterol and for the ratio of total to HDL cholesterol.

4 lso associated with higher rather than lower HDL cholesterol.

5 for triglycerides, fasting glucose, and non-HDL cholesterol.

6 levels were also positively associated with HDL cholesterol.

7 associates with CAD after accounting for non-HDL cholesterol.

8 by rs2246293 genotypes in the EPA-associated HDL cholesterol.

9 not with age, sex, duration of diabetes, or HDL cholesterol.

10 T), red blood cell indices (MCH and MCV) and HDL cholesterol.

11 , effects that were attributable to elevated HDL cholesterol.

12 ng triglycerides, and having lower levels of HDL cholesterol.

13 mpared with 1.08 +/- 0.06), and lower plasma HDL cholesterol.

14 % (95% CI: -5.8%, -0.6%; P = 0.02) change in HDL cholesterol.

15 tivity, independently of fat mass and plasma HDL cholesterol.

16 k reduction, assuming a 50% reduction of non-HDL cholesterol.

17 3-1.44) per 1 standard deviation increase in HDL-cholesterol.

18 poA1-KO hosts with lower levels of total and HDL-cholesterol.

19 gonist GW501516 to increase plasma levels of HDL-cholesterol.

20 oprotein (LDL) and high-density lipoprotein (HDL) cholesterol.

21 -0.00761--0.0027), high density lipoprotein (HDL) cholesterol 0.00179 (95% CI 0.000571-0.00301), trig

22 ta-carotene and BMI (-0.27), WC (-0.30), and HDL cholesterol (0.31) after accounting for multiple com

23 10 mmol/L, respectively (P = 0.007); and non-HDL cholesterol: +0.24 +/- 0.49 compared with -0.14 +/-

24 were LDL cholesterol 3.57 (0.87) mmol/L and HDL cholesterol 1.45 (0.38) mmol/L, and the median trigl

25 olesterol (-17 +/- 4 mg/dL; P < 0.0001), non-HDL cholesterol (-16 +/- 3 mg/dL; P < 0.0001), triglycer

26 (-14.6 mg/dL, 95% CI -18.2 to -11.0) and non-HDL cholesterol (-18.4 mg/dL, -22.5 to -14.3).

27 rom hazard ratio 1.1, 95% CI 1.0-1.3 for non-HDL cholesterol 2.6 to <3.7 mmol/L to 1.9, 1.6-2.2 for >

28 elevated blood pressure, 40.98% for reduced HDL-cholesterol, 23.33% for elevated triglycerides, 18.9

29 4.1% compared with 0.9%; P < 0.0001) and non-HDL cholesterol (-3.1% compared with 0.4%; P = 0.0032).

30 2% (95% CI: -2.3%, 7.8%), respectively], non-HDL cholesterol [-5.3% (95% CI: -8.6%, 2.1%) compared wi

31 ipoprotein B (n = 255), triglycerides (440), HDL cholesterol (534), and apolipoprotein A-I (440).

32 ocumab was associated with reductions in non-HDL cholesterol (55% [47-63] vs placebo and 34% [26-41]

33 6% [16-35] vs ezetimibe), and an increase in HDL cholesterol (7% [4-11] vs placebo and 8% [4-13] vs e

34 ctively; P = 0.006) and greater increases in HDL cholesterol (7.6% +/- 1.4% compared with -0.7% +/- 1

35 % CI, -13.3 to +10.2; P=0.80), but increased HDL cholesterol (+7.7%), apolipoprotein A-I (+4.3%), and

36 al cholesterol and high-density lipoprotein (HDL) cholesterol (all p < 0.05).

37 .24 to -0.13) and positive correlations with HDL cholesterol (alpha-carotene = 0.17; beta-carotene =

38 total cholesterol (TC), LDL cholesterol, and HDL cholesterol also did not change in response to the e

39 region associated with increased circulating HDL-cholesterol also associate with increased AMD risk,

40 cy was associated with reduced levels of non-HDL cholesterol and a reduced risk of coronary artery di

41 HDL cholesterol and apoA1 and apoC3 quartiles were not r

42 ntrast with significant associations for non-HDL cholesterol and atherogenic particles: apolipoprotei

43 We assessed changes in HbA1c, triglycerides, HDL cholesterol and BMI in a mixed effects longitudinal

44 stigated the association between primary low HDL cholesterol and coronary heart disease (CHD), CVD, a

45 improvements were additionally observed for HDL cholesterol and for the ratio of total to HDL choles

46 ses in insulin and glucose, and decreases in HDL cholesterol and ghrelin (Ps < 0.05).

47 n, elevated triglycerides, reduced levels of HDL cholesterol and glucose impairment) on the phenotype

48 t Study [n=5835]) were screened for combined HDL cholesterol and Lp(a) elevations.

49 In an index subject with high levels of HDL cholesterol and Lp(a), SCARB1 was sequenced and demo

50 notype, characterized by high levels of both HDL cholesterol and Lp(a).

51 iovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid

52 that signals observed at ABCA1 and LIPC for HDL cholesterol and NCAN/MAU2 for triglycerides are inde

53 HDL cholesterol and triglyceride also showed significant

54 no significant differences between diets for HDL cholesterol and triglyceride.In comparison with a co

55 easures of adiposity, ~0.1 mmol/l higher non-HDL cholesterol and triglycerides and 0.2 mmol/l higher

56 .9% of the variability of total cholesterol, HDL cholesterol and triglycerides in the Framingham Offs

57 were conducted for high-density lipoprotein (HDL) cholesterol and apolipoprotein A-I.

58 A than after iTFA; high-density lipoprotein (HDL) cholesterol and apolipoprotein AI also were higher

59 ween low levels of high-density lipoprotein (HDL) cholesterol and cardiovascular disease (CVD) have o

60 clear link between high-density lipoprotein (HDL) cholesterol and cardiovascular disease, leading to

61 rease in levels of high-density lipoprotein (HDL) cholesterol and triglycerides.

62 formed on kidney function (defined by eGFR), HDL-cholesterol and triglycerides.

63 ss the effect of KJM on LDL cholesterol, non-HDL cholesterol, and apolipoprotein B.Medline, Embase, C

64 were associated with on-treatment LDL-C, non-HDL cholesterol, and apolipoprotein B; these were also a

65 nt of high-density lipoprotein (HDL) and non-HDL cholesterol, and extended to stroke and myocardial i

66 DL-free cholesterol, XL-HDL phospholipids, L-HDL cholesterol, and L-HDL-free cholesterol, as well as

67 with systolic and diastolic blood pressure, HDL cholesterol, and triglycerides were included as cova

68 pid panels including total cholesterol (TC), HDL cholesterol, and triglycerides were measured at base

69 iabetes and higher glycated haemoglobin, non-HDL cholesterol, and waist-to-height ratio).

70 assess the causal roles of LDL-cholesterol, HDL-cholesterol, and triglycerides on AMD risk.

71 droxyvitamin D [25(OH)D], total cholesterol, HDL cholesterol, apoA-I, apoB, and C-reactive protein (C

72 flux capacity was moderately correlated with HDL cholesterol, apolipoprotein A-I, and HDL particle nu

73 diet, significantly reduced LDL cholesterol, HDL cholesterol, apolipoprotein A-I, intermediate-densit

74 Higher levels of HDL cholesterol appear to protect against RHOA after 11

75 We defined "primary low HDL cholesterol" as HDL cholesterol level <40 mg/dL (men

76 The difference in HDL cholesterol associated with higher circulating EPA w

77 lesterol, triglycerides, lipoprotein(a), and HDL cholesterol at 12 weeks for evolocumab, placebo, and

78 dietary fatty acids) and changes in LDL and HDL cholesterol based on the use of data from randomized

79 reduction was associated with an increase in HDL cholesterol (beta = -0.452; 95% CI: -0.880, -0.023;

80 039) and a decrease in total cholesterol and HDL cholesterol (beta = 3.766; 95% CI: 1.092, 6.440; P =

81 he ratio of TGs to high-density lipoprotein (HDL) cholesterol (beta = 2.689; 95% CI: 0.373, 5.003; P

82 CI: 0.001, 0.011 SD/allele; P = 0.025; lower HDL cholesterol: beta = -0.007 SD/allele; 95% CI: -0.012

83 There was no significant difference in HDL cholesterol between the REG and RED diets, but HDL c

84 erides and only 1-3% of the association with HDL-cholesterol, blood pressure, and insulin concentrati

85 rom cheese and butter has similar effects on HDL cholesterol but differentially modifies LDL-choleste

86 y lipoprotein, and high-density lipoprotein (HDL) cholesterol, but not in the total-to-HDL cholestero

87 etrapib doubled HDL cholesterol, reduced non-HDL cholesterol by 17 mg/dl (0.44 mmol/l), and reduced m

88 (95% CI: 3.01, 17.94; I(2) = 84%, N=16) and HDL-cholesterol by 4.00 mg/dL (95% CI: 2.26, 5.73; I(2)

89 reactive protein (CRP) were analyzed and non-HDL cholesterol calculated at baseline and after the int

90 cular disease event-rates for increasing non-HDL cholesterol categories (from 7.7% for non-HDL choles

91 ltivariable analyses were computed using non-HDL cholesterol categories according to the European gui

92 LPL, ABCA1, ZNF259/APOA5, LIPC and CETP for HDL cholesterol, CELSR2, APOB and NCAN/MAU2 for LDL chol

93 The clinical implications of HDL-cholesterol changes associated with dietary choleste

94 urthermore, thermogenic stimulation promotes HDL-cholesterol clearance and increases macrophage-to-fa

95 r intake was also followed by an increase in HDL cholesterol compared with the habitual diet.

96 05 and P < 0.05, respectively) and increased HDL cholesterol compared with the run-in period (P < 0.0

97 ed the following functional characteristics: HDL cholesterol concentration (in plasma); cholesterol e

98 the hypertriglyceridemia (P = 0.003) and low HDL cholesterol concentration (P = 0.002) criteria of MS

99 d an increase in the association between non-HDL cholesterol concentration and cardiovascular disease

100 rovided smaller estimates of the mean plasma HDL cholesterol concentration in association with both t

101 High-density lipoprotein (HDL) cholesterol concentration (HDL-C) is an established

102 caused a 5% higher high-density lipoprotein (HDL)-cholesterol concentration (P = 0.012), an 8% higher

103 There was no change in HDL-cholesterol concentration, but triglyceride concentr

104 olesterol concentrations (0.14-0.17 mmol/L), HDL cholesterol concentrations (0.05-0.09 mmol/L), fat m

105 CC control and LFHCC n-3 diets and increased HDL cholesterol concentrations after consumption of the

106 Non-HDL cholesterol concentrations in blood are strongly ass

107 erolemic (HL) diet for 10 days, reaching non-HDL cholesterol concentrations of 38.2 +/- 3.5 mg/dl and

108 A 50% reduction of non-HDL cholesterol concentrations was associated with reduc

109 Mean LDL and HDL cholesterol concentrations were 2.35 mmol/L (91 mg/d

110 ociated with plasma adiponectin, insulin and HDL cholesterol concentrations, obesity, and coronary at

111 r risk that extend beyond traditional plasma HDL cholesterol concentrations.

112 ilable measures of serum LDL cholesterol and HDL cholesterol concentrations.

113 ) single nucleotide polymorphisms and plasma HDL cholesterol concentrations.

114 ed with the full spectrum of bloodstream non-HDL cholesterol concentrations.

115 ke may also affect high-density lipoprotein (HDL)-cholesterol concentrations, but its impact has not

116 HDL-cholesterol concentrations after the milk diet were

117 r effects on fasting LDL-cholesterol and non-HDL-cholesterol concentrations and more favorable ones t

118 versely related to the change in circulating HDL-cholesterol concentrations in men but is positively

119 en with abdominal obesity and relatively low HDL-cholesterol concentrations were assigned to sequence

120 Fasting HDL-cholesterol concentrations were lower after the stea

121 Fasting LDL-cholesterol and non-HDL-cholesterol concentrations were lower after the stea

122 rbohydrate diet (fat: 25%, SFAs: 5.8%).Serum HDL-cholesterol concentrations were similar after the ch

123 Lipid biomarkers, such as HDL-cholesterol concentrations, have been shown to have

124 Both products increased HDL-cholesterol concentrations, whereas only DFCP decrea

125 ower LDL-cholesterol concentrations or raise HDL-cholesterol concentrations.

126 The genetic risk score for non-HDL cholesterol confers CAD risk beyond that of LDL chol

127 /apoB-100 dual transgenic mice and increased HDL cholesterol content and size comparable to torcetrap

128 [95% CI, 0.1 to 0.4 mg/dL] per year) and non-HDL cholesterol decreased from 108 mg/dL (95% CI, 106 to

129 HDL cholesterol-decreasing gene scores and allele number

130 enger receptor B-I are the driving forces of HDL-cholesterol disposal in liver.

131 In conclusion, genetically reduced HDL cholesterol does not associate with increased risk o

132 r, LDL did not exert a synergistic effect on HDL cholesterol efflux capacity in the familial hypercho

133 We investigated whether HDL cholesterol efflux capacity is associated with cardi

134 In conclusion, HDL cholesterol efflux capacity is not a prognostic card

135 tudy (4D Study), we investigated whether the HDL cholesterol efflux capacity is predictive for cardio

136 In conclusion, HDL-cholesterol efflux normalised to apoA-I was inversel

137 Whether HDL cholesterol exerts a protective effect on ischemic s

138 -reactive protein, high-density lipoprotein (HDL) cholesterol, forced expiratory volume, grip strengt

139 anges in the abundance of biomarkers such as HDL cholesterol, free fatty acids, FGF21, bilirubin, and

140 20 mmol/L (0.14 to 0.26) for olanzapine; for HDL cholesterol from 0.05 mmol/L (0.00 to 0.10) for brex

141 The non-HDL cholesterol genetic risk score associates most stron

142 (22:6n-3) and serum triacylglycerol, LDL and HDL cholesterol, glucose, and insulin.

143 were no group differences in triglycerides, HDL cholesterol, glucose, insulin, insulin resistance, l

144 hosts, containing higher levels of total and HDL-cholesterol, grew larger tumors than apoA1-KO hosts

145 We defined an "optimal" lipid profile as HDL cholesterol >/=40 mg/dL (men) or >/=50 mg/dL (women)

146 Participants with primary low HDL cholesterol had higher risks of CHD and CVD than par

147 e LIPC gene region that increase circulating HDL-cholesterol have the opposite direction of associati

148 24, - 0.016), p = 0.036) and positively with HDL cholesterol (HDL-C) (beta = 0.442, 95% CI (0.011,0.8

149 The cholesterol concentration of HDL (HDL cholesterol (HDL-C)) without apoC-III was inversely

150 (HbA1c), insulin resistance, triglycerides, HDL cholesterol (HDL-C), and C-reactive protein].

151 to estimate associations between circulating HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), and tr

152 High-density lipoprotein (HDL) cholesterol (HDL-C) levels decline during sepsis, a

153 major receptor for high-density lipoprotein (HDL) cholesterol (HDL-C).

154 oncentration predict coronary ED better than HDL-cholesterol (HDL-C).

155 holesterol [TC; 86 studies; 168,553 people], HDL-Cholesterol [HDL-C; 84 studies; 121,282 people], LDL

156 -frequency variants for association with non-HDL cholesterol, HDL cholesterol, LDL cholesterol, and t

157 tor profile [lower high-density lipoprotein (HDL) cholesterol, higher total homocysteine, and higher

158 ; P-trend = 0.006) and lung cancer risk with HDL cholesterol (HR: 0.59; 95% CI: 0.38, 0.93; P-trend =

159 iations included colorectal cancer risk with HDL cholesterol (HR: 0.63; 95% CI; 0.41, 0.98; P-trend =

160 9; 95% CI: 0.70, 0.90; P-trend = 0.0008) and HDL cholesterol (HR: 0.85; 95% CI: 0.75, 0.97; P-trend =

161 nd improvements in high-density lipoprotein (HDL) cholesterol (HRS beta 1.50, 95%CI: 0.34, 2.49, p <

162 sh intake improved serum triacylglycerol and HDL cholesterol in a dose-dependent manner in 8- to 9-y-

163 e function of CETP can increase the level of HDL cholesterol in blood plasma and suppress the risk of

164 e function of HDL may be more important than HDL cholesterol in deciphering disease risk.

165 in BMI, fasting glucose, triglycerides, and HDL cholesterol in individuals randomized to metformin o

166 9) in the ENCODE consortium and lower plasma HDL cholesterol in the GOLDN study (r = -0.12, P = 0.000

167 The causal role of high-density lipoprotein (HDL) cholesterol in cardioprotection has been questioned

168 L (95% CI: 0.00, 0.11 mmol/L) (P = 0.04) and HDL cholesterol increased by 0.07 mmol/L (95% CI: 0.01,

169 and risks including acne, alopecia, reduced HDL cholesterol, increased triglycerides, and a possible

170 gher levels of physical activity enhance the HDL cholesterol-increasing effects of the CLASP1, LHX1,

171 HDL cholesterol is a biomarker for CVD risk, but the fun

172 Our study suggested that HDL cholesterol is associated with increased risk of AMD

173 Some genetic evidence suggests that HDL-cholesterol is a causal risk factor for AMD risk and

174 We find evidence that HDL-cholesterol is a causal risk factor for AMD, with an

175 There were significant increases in HDL cholesterol, LDL cholesterol, and triacylglycerols,

176 erformed genome-wide analyses of circulating HDL cholesterol, LDL cholesterol, and triglyceride level

177 ts for association with non-HDL cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides in u

178 sitivity C-reactive protein, hemoglobin A1c, HDL cholesterol, LDL cholesterol, and triglycerides, the

179 We defined "primary low HDL cholesterol" as HDL cholesterol level <40 mg/dL (men) or <50 mg/dL (wome

180 Adjusted mean HDL cholesterol level increased from 52.5 mg/dL (95% CI,

181 deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol

182 deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol

183 igher levels statistically in cases with low HDL cholesterol level, high LDL cholesterol level, high

184 yceride level, low high-density lipoprotein (HDL) cholesterol level, impaired fasting glucose level,

185 perlipidemia and insulin resistance, reduced HDL-cholesterol level, increased LDL-cholesterol level,

186 .13, 95% CI: 1.05, 1.21) and 10-mg/dL-higher HDL cholesterol levels (odds ratio = 0.96, 95% CI: 0.92,

187 5% CI 0.38-0.76]; P < 0.001), independent of HDL cholesterol levels (P = 0.015), adiposity (P = 0.018

188 onal logistic regression models adjusted for HDL cholesterol levels and cardiovascular risk factors t

189 sting insulin levels adjusted for BMI, lower HDL cholesterol levels and higher triglyceride levels) a

190 An inverse association between HDL cholesterol levels and the incidence of RHOA was obs

191 lso had lower triglyceride levels and higher HDL cholesterol levels and were less likely to have coro

192 ol levels between 2.5 mmol/L and 4.5 mmol/L, HDL cholesterol levels between 0.8 and 1.8 mmol/L and tr

193 ation between these imputed variants and non-HDL cholesterol levels in 119,146 samples.

194 ictor of graft failure independent of plasma HDL cholesterol levels in renal transplant recipients.

195 HDL cholesterol levels, apolipoprotein A-I, cholesterol

196 increased plasma triglycerides and decreased HDL cholesterol levels, is a major factor contributing t

197 s of which include hypertriglyceridemia, low HDL cholesterol levels, qualitative changes in LDL parti

198 role of the lipoprotein beyond quantitative HDL cholesterol levels.

199 R-885-5p levels associated inversely with XL HDL cholesterol levels.

200 l transporter could link hsa-miR-885-5p with HDL cholesterol levels.

201 ciated with up to -13 and -20% reductions in HDL cholesterol levels.

202 ty lipoprotein) and a suggestive QTL for non-HDL cholesterol levels.

203 new experience and high-density lipoprotein (HDL) cholesterol levels are most positively genetically

204 drugs that raised high-density lipoprotein (HDL) cholesterol levels to reduce cardiovascular events

205 vels and increases high-density lipoprotein (HDL) cholesterol levels.

206 ve protein levels (P = 0.003), and decreased HDL-cholesterol levels (P = 0.009) than the women withou

207 total cholesterol (FN1 and SAMM50), two for HDL cholesterol (LOC100996634 and COPB1) and one for LDL

208 scores and polygenic profile scores for BMI, HDL cholesterol, low-density lipoprotein cholesterol, co

209 total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) choleste

210 total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein cholesterol, t

211 Multivariable adjusted Cox models with non-HDL cholesterol lower than 2.6 mmol/L as reference showe

212 cardiometabolic risk-factor profile (higher HDL cholesterol, lower BMI, lower C-reactive protein, lo

213 CETP gene were associated with higher blood HDL cholesterol, lower low-density lipoprotein cholester

214 astolic >/= 85 mm Hg, or antihypertensives); HDL cholesterol < 40 mg/dL (men) or < 50 mg/dL (women);

215 DL cholesterol categories (from 7.7% for non-HDL cholesterol <2.6 mmol/L to 33.7% for >=5.7 mmol/L in

216 mHg for systolic or >=85 mmHg for diastolic, HDL cholesterol <40 mg/dL for males and <50 mg/dL for fe

217 prevention, which reduce apo B-100 or raise HDL cholesterol, may be associated with reduced cancer r

218 mmol/L; 95% CI: -0.46, -0.25 mmol/L) and non-HDL cholesterol (MD: -0.32 mmol/L; 95% CI: -0.46, -0.19

219 , 21.5), and lower high-density lipoprotein (HDL) cholesterol (MD = -2.1 mg/dL, 95% CI: -2.7, -1.6) c

220 /d for reductions in LDL cholesterol and non-HDL cholesterol of 10% and 7%, respectively.

221 n objective was to investigate the effect of HDL cholesterol on outcomes in maintenance hemodialysis

222 This relationship was independent of HDL cholesterol or apo AI levels.

223 ps or between groups for changes in total or HDL cholesterol or triglycerides.

224 nalyses showed a 1-standard-deviation-higher HDL cholesterol (OR 0.80; 95% CI: 0.75-0.86; P < 0.001)

225 ty (OR/SD, 0.89; 95% CI, 0.72-1.10; P=0.28), HDL cholesterol (OR/SD, 0.82; 95% CI, 0.66-1.02; P=0.08)

226 ed the effect of KJM on LDL cholesterol, non-HDL cholesterol, or apolipoprotein B.

227 P<0.001) independent of apolipoprotein A-I, HDL cholesterol, or creatinine clearance.

228 k index, total cholesterol, LDL cholesterol, HDL cholesterol, or triglycerides (all P > 0.05).

229 (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides at a genome-wide leve

230 fferences were found in glycated hemoglobin, HDL-cholesterol, or triglyceride concentrations.

231 h lower circulating triglycerides and higher HDL cholesterol (p < 0.01).

232 < 0.01, r = -0.236 at the end) and serum LDL/HDL cholesterol (P < 0.01, r = -0.239 at the beginning;

233 (P = 0.03), LDL cholesterol (P = 0.04), and HDL cholesterol (P = 0.05) than placebo toothpaste.

234 No changes were observed for HDL cholesterol (P = 0.30), C-reactive protein (P = 0.10

235 ipopolysaccharide-binding protein, and lower HDL cholesterol (P ranging from <0.001 to 0.03), reflect

236 EBF1 expression was directly associated with HDL cholesterol (P-value = 0.0429).

237 was also associated with lower levels of non-HDL cholesterol (P=1.8x10(-3)).

238 e, only rs1729407 showed an association with HDL-cholesterol (P = 7.1 x 10 (-) (07)).

239 risk factor for AMD risk and that increasing HDL-cholesterol (particularly via CETP inhibition) will

240 ation related to total cholesterol (SREBF2), HDL-cholesterol (PHOSPHO1, SYNGAP1 and an intergenic reg

241 lder and had lower high-density lipoprotein (HDL) cholesterol, phospholipids, and methylation potenti

242 ions were negatively correlated with fasting HDL cholesterol (r = -0.51 to -0.44; P < 0.01) concentra

243 d positively correlated with LDL cholesterol:HDL cholesterol (r = 0.37-0.54; P < 0.01) ratios.

244 lesterol (r=0.42, p=0.013), and decreases in HDL cholesterol (r=-0.35, p=0.035).

245 However, the total/HDL cholesterol ratio did not significantly decrease due

246 ] was not significant, the total cholesterol:HDL cholesterol ratio was 0.13 (95% CI: 0, 0.26; P = 0.0

247 re, heart rate, HbA1c, blood glucose, LDL-to-HDL cholesterol ratio, C-reactive protein, angiotensin I

248 n (HDL) cholesterol, but not in the total-to-HDL cholesterol ratio.

249 respectively; P = 0.005) and the cholesterol:HDL-cholesterol ratio (-2.5% +/- 1.3% compared with 0.3%

250 cholesterol (p<0.0001), total cholesterol to HDL-cholesterol ratio (p<0.0001), and systolic (p<0.0011

251 %), respectively], and the total-cholesterol:HDL-cholesterol ratio [-0.0% (95% CI: -4.3%, 4.8%) compa

252 change from baseline in total cholesterol to HDL-cholesterol ratio.

253 pid Modification) trial, anacetrapib doubled HDL cholesterol, reduced non-HDL cholesterol by 17 mg/dl

254 ith LDL cholesterol (rs17242388 in LDLR) and HDL cholesterol (rs189679427 between GOT2 and APOOP5), a

255 lesterol, HDL cholesterol, triglycerides, TC:HDL cholesterol, SBP, and DBP, respectively].

256 and T2DM, whereas RCTs reported improved TC, HDL cholesterol, SBP, and HOMA-IR.

257 logical quality studies, improvements in TC, HDL cholesterol, SBP, DBP, HOMA-IR, and acute/chronic FM

258 erol, and L-HDL-free cholesterol, as well as HDL cholesterol seem to be protective against increasing

259 rting the idea that HDL function rather than HDL cholesterol should be addressed in this population.

260 t changes in apoA-I, TC, LDL cholesterol, or HDL cholesterol, supporting the idea that HDL function r

261 nce, triglyceride, high-density lipoprotein (HDL) cholesterol, systolic and diastolic blood pressure,

262 L cholesterol, triglycerides, ratio of TC to HDL cholesterol (TC:HDL), and systolic and diastolic blo

263 Among all subjects, TC, LDL cholesterol, HDL cholesterol, TC:HDL cholesterol, triglycerides, and

264 tintervention values of TC, LDL cholesterol, HDL cholesterol, TC:HDL cholesterol, triglycerides, SBP,

265 olesterol between the REG and RED diets, but HDL cholesterol tended to be higher with the REG diet th

266 levels of triglycerides and higher levels of HDL cholesterol than did heterozygotes.

267 ociated with decreased adiposity and greater HDL cholesterol than lower protein diets.

268 r study population) had a lower level of non-HDL cholesterol than noncarriers, a difference of 15.3 m

269 erum levels of non-high-density lipoprotein (HDL) cholesterol that alter the risk of coronary artery

270 articipants than in female participants; for HDL cholesterol, the mean values were lower with greater

271 erol), high-density lipoprotein cholesterol (HDL-cholesterol), total cholesterol, triglycerides, meas

272 d diastolic blood pressure, LDL cholesterol, HDL cholesterol, total cholesterol, triglycerides, and f

273 ne in concentrations of LDL cholesterol, non-HDL cholesterol, total cholesterol, triglycerides, lipop

274 (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triacylglycerols, apolipoproteins A-I

275 ht, BMI, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, and glucose concentration

276 traits (total cholesterol, LDL-cholesterol, HDL-cholesterol triglycerides) in up to 27 312 individua

277 ssure (DBP), total cholesterol (TC), LDL and HDL cholesterol, triglycerides (TGs), hemoglobin A1c (Hb

278 ts, TC, LDL cholesterol, HDL cholesterol, TC:HDL cholesterol, triglycerides, and DBP, but not SBP, de

279 I, systolic blood pressure, LDL cholesterol, HDL cholesterol, triglycerides, and fasting glucose) to

280 tes for low-density lipoprotein cholesterol, HDL cholesterol, triglycerides, glucose, and body mass i

281 PCs were significantly correlated with serum HDL cholesterol, triglycerides, glucose, insulin, and HO

282 ood total cholesterol (TC), LDL cholesterol, HDL cholesterol, triglycerides, ratio of TC to HDL chole

283 of TC, LDL cholesterol, HDL cholesterol, TC:HDL cholesterol, triglycerides, SBP, and DBP; calculated

284 g (-1.2, 1.5 mm Hg) for TC, LDL cholesterol, HDL cholesterol, triglycerides, TC:HDL cholesterol, SBP,

285 h low- and high-density lipoprotein (LDL and HDL) cholesterol, triglycerides, and apolipoprotein A-I

286 ircumference (WC), high-density lipoprotein (HDL) cholesterol, triglycerides, fat mass (FM), systolic

287 processing of SR-BI and abrogates selective HDL cholesterol uptake in transfected cells, in hepatocy

288 ucose, and non-high-density lipoprotein (non-HDL) cholesterol using linear mixed models.

289 For participants with primary low HDL cholesterol versus those with an optimal lipid profi

290 orts in the CHARGE consortium, higher plasma HDL cholesterol was associated with fewer C alleles at A

291 At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12

292 fference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 m

293 Body mass index and HDL cholesterol were negatively correlated with molecula

294 Decreased levels of apoA-I and HDL cholesterol were robustly associated with increased

295 pants versus 27% in controls), but total and HDL cholesterol were similar.

296 all cardiometabolic risk factors except non-HDL cholesterol were stronger in women than men.

297 and the levels of high-density lipoprotein (HDL) cholesterol were 7% higher among carriers of the E4

298 ally measured in intervention trials, namely HDL cholesterol, which has an inconsistent relationship

299 disease event probabilities specific for non-HDL cholesterol with high comparability between the deri

300 ra large (XL) HDL lipid components, i.e., XL-HDL cholesterol, XL-HDL-free cholesterol, XL-HDL phospho